Navigation Links
Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
Date:4/18/2013

HUNTSVILLE, Ala., April 18, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development based upon poly(oxazoline) - POZ, announced today that the company has entered into a definitive agreement with Woodside Capital Partners retaining them as the Company's advisor and investment bank. The details of the agreement were not disclosed.

"We are very pleased to announce that Serina Therapeutics has reached an agreement to have Woodside Capital Partners serve as our advisor and investment bank. Woodside Capital and its elite group of partners and life science advisors have a remarkable track record of helping to create shareholder value in promising biotechnology companies," said Randall Moreadith , MD, PhD, President and Chief Executive Officer of Serina. "Now that we are beginning to move our first clinical candidate toward Phase I in early 2014, and have signed an alliance with a large pharmaceutical partner for development of a POZ-therapeutic, we felt it was time to bring in an expert in doing deals across a wide range of companies in the pharmaceutical industry. We think Woodside Partners fills that need exceptionally well."

"Woodside Capital looks forward to working with the seasoned management team and board at Serina to complete additional transactions with selected pharmaceutical partners," said John Selig , Managing Director and co-head of Woodside Capital's Life Sciences Group. "We believe Serina's POZ technology has the potential to significantly improve the product profile of a large number of molecules across therapeutic areas."

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary poly(oxazoline) (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

About Woodside Capital Partners

Woodside Capital Partners is a global investment bank with offices in Silicon Valley and London that delivers world-class strategic and financial advice to emerging growth companies in the life sciences and technology sectors. With a strong track record in strategic partnerships, M&A and private placements, Woodside Capital has been providing investment banking services worldwide since 2001 with leading domain experience in life sciences, software, Internet services, electronic communications and materials.  The team of Woodside Capital has completed transactions totaling more than $10 billion.  The firm is also the Silicon Valley headquarters of M&A International, the world's leading mergers and acquisitions alliance.  

For more information on Woodside Capital, please visit www.woodsidecap.com.


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):